Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 24,800 shares, a growth of 40.1% from the May 31st total of 17,700 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 27,900 shares, the short-interest ratio is currently 0.9 days.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Evoke Pharma in a research note on Saturday. They issued a “sell” rating for the company.
View Our Latest Report on Evoke Pharma
Evoke Pharma Price Performance
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The firm had revenue of $1.74 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Does a Stock Split Mean?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.